PIRAMAL PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148 INR | +1.61% |
|
+0.27% | +6.63% |
| 14/05 | Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy | MT |
| 13/05 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
| Sales 2024 | 8.17TCr 98Cr | Sales 2025 * | 9.22TCr 110.5Cr | Capitalization | 20TCr 235.32Cr |
|---|---|---|---|---|---|
| Net income 2024 | 18Cr 21.34L | Net income 2025 * | 232.5Cr 2.79Cr | EV / Sales 2024 | 2.09 x |
| Net Debt 2024 * | 3.37TCr 40Cr | Net Debt 2025 * | 3.68TCr 44Cr | EV / Sales 2025 * | 2.53 x |
| P/E ratio 2024 |
921
x | P/E ratio 2025 * |
83.5
x | Employees | 6,295 |
| Yield 2024 * |
0.14% | Yield 2025 * |
0.2% | Free-Float | 26.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Piramal Pharma Limited
More recommendations
More press releases
| 1 day | +1.61% | ||
| 1 week | +0.27% | ||
| 1 month | +3.06% | ||
| 3 months | +12.24% | ||
| 6 months | +16.94% | ||
| Current year | +6.63% |
1 week
145.20
151.05
1 month
141.35166.70
Current year
114.35166.70
1 year
81.35166.70
3 years
63.10200.00
5 years
63.10200.00
10 years
63.10200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 04/20/04 |
Vivek Valsaraj
PSD | President | 51 | 10/20/10 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 05/20/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 43 | 04/21/04 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
| Director/Board Member | 76 | 09/21/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +5.36% | - | |
| 0.00% | 112 M€ | +4.61% | - | |
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 148 | +1.61% | 3,816,461 |
| 30/24/30 | 145.7 | -2.83% | 1,991,282 |
| 29/24/29 | 150 | -0.03% | 2,250,492 |
| 28/24/28 | 150 | +0.20% | 3,518,065 |
| 27/24/27 | 149.7 | +1.39% | 4,422,073 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
Sector
Pharmaceuticals
Calendar
05/06/2024
- Nomura Investment Forum
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
148
INR
Average target price
176
INR
Spread / Average Target
+18.88%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.63% | 235.18Cr | |
| +40.73% | 74TCr | |
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr | |
| -0.45% | 16TCr |
- Stock Market
- Equities
- PPLPHARMA Stock
